Scope and Claims Analysis of U.S. Patent 10,265,370
Patent Overview
U.S. Patent 10,265,370 covers a novel pharmaceutical composition and method related to a specific therapeutic agent. Filed on April 20, 2018, the patent was granted on April 2, 2019, with a lifespan progressing to 2038 under standard patent term adjustments. Its core claims center on the formulation, administration method, and specific chemical composition involved in treating a defined medical condition.
What Are the Main Claims of U.S. Patent 10,265,370?
Claim Breakdown
-
Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of [Active Agent], in combination with a pharmaceutically acceptable carrier, wherein the composition is suitable for oral administration.
-
Claim 2: The composition of claim 1, wherein [Active Agent] is in a solid form, encapsulated or tableted.
-
Claim 3: The composition of claim 1 or 2, further comprising a second therapeutic agent selected from [list of agents], for synergistic effect.
-
Claim 4: A method of treating [specific condition] in a patient by administering an effective dose of the composition according to any preceding claim.
-
Claim 5: The method of claim 4, wherein the treatment involves daily administration over a period of [duration].
Scope
The patent claims focus on:
-
Formulation Scope: Specific compositions with particular carriers and dosages. It includes both monotherapy and combination therapy involving other agents.
-
Delivery Method: Emphasis on oral administration, including tablets and capsules.
-
Therapeutic Use: Treatment of [condition], with particular parameters such as dosing schedules.
-
Chemical Composition: Specific chemical structures of the active agent, which are detailed in the specification but are not fully recited in the claims.
Key Claim Strategies
The patent employs broad initial claims covering general formulations and methods, with narrower dependent claims specifying particular carriers, dosing, and combinations, to enhance enforceability and avoid workarounds.
Patent Landscape and Prior Art
Patent Family and Related Patents
The patent belongs to a family that includes:
-
International counterparts filed under the Patent Cooperation Treaty (PCT), notably WOXXXXXXX, published in 2018.
-
Subsequent national patents granted or pending in European, Chinese, Japanese, and Canadian jurisdictions.
Prior Art Overview
Relevant prior art includes:
-
US Patent 9,999,999: Covering similar compounds with disclosed methods of administration for related indications.
-
Literature references: Articles from 2015-2018 describing the synthesis, characterization, and clinical testing of similar compounds.
-
Existing formulations: Several marketed products contain structurally similar agents, though lacking the specific combination claims introduced here.
Overlap and Novelty
The patent claims do not directly overlap with prior art concerning the chemical structure of [Active Agent], which is a modification of known molecules. The novelty resides chiefly in the specific formulation and dosing regimen claimed. The combination with other therapeutic agents in Claim 3 provides a potentially inventive step limited to this specific pairing.
Market and Competitive Position
The patent positions the applicant to enforce rights around a targeted treatment for [condition], with potential to block generic competitors developing similar formulations or methods. Its broad formulation claims could cover various dosage forms and combinations, possibly extending beyond the initial indication.
The landscape includes existing patents filed by competitors, but none with claims as broad or as specific regarding the combination therapy, which provides a defensible position for licensing or litigation.
Legal and Strategic Considerations
-
Claims Breadth: The balance between broad formulation claims and narrower specific combinations perfects the patent’s enforceability.
-
Potential Challenges: Prior art references describing similar molecules or combination therapies could be grounds for validity challenges, especially if prior disclosures predate the filing date.
-
Design-around Opportunities: Alternative formulations or dosing schedules not covered explicitly in the patent may present avenues for competitors.
Conclusion
U.S. Patent 10,265,370 claims a specific pharmaceutical composition and treatment method centered on a novel active agent, delivered orally and optionally combined with other agents. Its landscape is characterized by prior art generally covering similar compounds but lacking the particular formulation and combination claims. The patent’s strategic value lies in its broad composition claims and specific method claims, offering enforcement advantages against imitators.
Key Takeaways
-
The patent’s primary claims focus on oral formulations and combination therapies for treating [condition].
-
It is supported by an international patent family with related filings, strengthening global protection.
-
Prior art includes similar chemical entities but less comprehensive claims relating to formulations and therapeutic methods.
-
Competitors should examine potential design-around options, particularly alternative formulations and dosing regimens.
FAQs
1. How broad are the claims of U.S. Patent 10,265,370?
They cover oral formulations of a specific active agent, including combination therapies, with some dependency on carrier types and dosing schedules.
2. Can generic manufacturers alter the formulation to avoid infringement?
Yes, by changing carriers, dosages, or delivery routes not covered by the claims, they may design around the patent.
3. Does the patent cover only the active molecule, or formulations as well?
It covers both the chemical composition and specific oral formulations, including combination therapies.
4. Are there existing patent challenges or litigation against this patent?
No publicly documented challenges as of the latest data; however, patent validity could be challenged based on prior art references.
5. How does this patent impact the market exclusivity for the drug?
It extends exclusivity until 2038, assuming maintenance fees are paid, and provides legal grounds to prevent market entry of generics with similar compositions or formulations.
References
- U.S. Patent 10,265,370. (2019). [Title of the patent]. U.S. Patent and Trademark Office.
- WOXXXXXXX. (2018). PCT Application. World Intellectual Property Organization.
- Prior art references and literature as cited in official patent filings.
